



---

# C o m m u n i q u é

---

## The PMPRB to Hold a Public Hearing into the Price of Dovobet

OTTAWA, **November 30, 2004**: The Patented Medicine Prices Review Board will hold a public hearing on February 21, 2005, in the matter of Leo Pharma Inc. and the price of the medicine Dovobet. A pre-hearing conference will also be held January 19, 2005.

The purpose of the hearing is to determine whether, under sections 83 and 85 of the *Patent Act*, Leo Pharma Inc.

- is selling or has sold the medicine known as Dovobet in any market in Canada at a price that, in the Board's opinion, is or was excessive; and,
- if so, what order, if any, should be made.

Dovobet 0.55 mcg/mg (DIN 02244126) has been sold in Canada since December 17, 2001. Dovobet is a dermatological drug that is administered for acute flare-ups of psoriasis.

Persons wishing to intervene in the proceeding are required to apply to the Board for leave to intervene on or before December 21, 2004. Such persons should contact the Secretary of the Board for further information on the procedure.

*You can access the Notice of Hearing and Board Staff's Statement of Allegations [here](#).*

All requests for information should be addressed to the Secretary of the Board.

---

Sylvie Dupont  
Secretary of the Patented Medicine Prices Review Board

Toll-free number: 1-877-861-2350  
Direct line: (613) 954-8299  
Fax: (613) 952-7626  
E-mail: [sdupont@pmprb-cepmb.gc.ca](mailto:sdupont@pmprb-cepmb.gc.ca)